{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,7]],"date-time":"2026-06-07T14:01:33Z","timestamp":1780840893676,"version":"3.54.1"},"reference-count":39,"publisher":"American Society of Hematology","issue":"4","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2005,8,15]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Beginning in 1985, patients in British Columbia with Hodgkin lymphoma (HL) that was not controlled by conventional chemotherapy routinely underwent high-dose chemotherapy and autologous stem cell transplantation (HD-ASCT). Long-term complications of HD-ASCT have become apparent as more patients survive without recurrence of HL. Data were obtained retrospectively on the first 100 patients that underwent HD-ASCT for HL in Vancouver, focusing on relapse, treatment-related complications, and the occurrence of late events. Fifty-three patients remain alive (median follow-up, 11.4 years [range, 10.0-17.4 years]) with an overall survival (OAS) of 54% at 15 years. OAS was significantly better in patients in first relapse (67%) than in patients with primary refractory-induction failure (39%) and advanced disease (29%) (P = .002). The major cause of death was progression of HL (32% at 15 years). Treatment-related mortality, including death from second malignancy, was 17% at 15 years. Cumulative risk of a second malignancy was 9% at 15 years. Karnofsky performance status was at least 90% in 47 patients although hypogonadism (20 patients), hypothyroidism (12 patients), unusual infections (10 patients), anxiety or depression (7 patients), and cardiac disease (5 patients) were not uncommon in survivors. HD-ASCT can lead to durable remissions in relapsed or refractory HL with acceptable but definite late toxicity. The occurrence of late events necessitates lifelong medical surveillance. (Blood. 2005;106:1473-1478)<\/jats:p>","DOI":"10.1182\/blood-2004-12-4689","type":"journal-article","created":{"date-parts":[[2005,5,4]],"date-time":"2005-05-04T02:38:30Z","timestamp":1115174310000},"page":"1473-1478","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":100,"title":["High-dose chemotherapy and autologous stem cell transplantation for primary refractory or relapsed Hodgkin lymphoma: long-term outcome in the first 100 patients treated in Vancouver"],"prefix":"10.1182","volume":"106","author":[{"given":"Julye C.","family":"Lavoie","sequence":"first","affiliation":[{"name":"From the Leukemia\/Bone Marrow Transplantation Program of British Columbia, Division of Hematology, Vancouver General Hospital, Vancouver, BC, Canada; the Department of Medical Oncology, British Columbia Cancer Agency, Vancouver, BC, Canada; the Department of Pathology and Radiation Oncology, British Columbia Cancer Agency, Vancouver, BC, Canada; and the University of British Columbia, Vancouver, BC, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph M.","family":"Connors","sequence":"additional","affiliation":[{"name":"From the Leukemia\/Bone Marrow Transplantation Program of British Columbia, Division of Hematology, Vancouver General Hospital, Vancouver, BC, Canada; the Department of Medical Oncology, British Columbia Cancer Agency, Vancouver, BC, Canada; the Department of Pathology and Radiation Oncology, British Columbia Cancer Agency, Vancouver, BC, Canada; and the University of British Columbia, Vancouver, BC, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gordon L.","family":"Phillips","sequence":"additional","affiliation":[{"name":"From the Leukemia\/Bone Marrow Transplantation Program of British Columbia, Division of Hematology, Vancouver General Hospital, Vancouver, BC, Canada; the Department of Medical Oncology, British Columbia Cancer Agency, Vancouver, BC, Canada; the Department of Pathology and Radiation Oncology, British Columbia Cancer Agency, Vancouver, BC, Canada; and the University of British Columbia, Vancouver, BC, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donna E.","family":"Reece","sequence":"additional","affiliation":[{"name":"From the Leukemia\/Bone Marrow Transplantation Program of British Columbia, Division of Hematology, Vancouver General Hospital, Vancouver, BC, Canada; the Department of Medical Oncology, British Columbia Cancer Agency, Vancouver, BC, Canada; the Department of Pathology and Radiation Oncology, British Columbia Cancer Agency, Vancouver, BC, Canada; and the University of British Columbia, Vancouver, BC, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Barnett","sequence":"additional","affiliation":[{"name":"From the Leukemia\/Bone Marrow Transplantation Program of British Columbia, Division of Hematology, Vancouver General Hospital, Vancouver, BC, Canada; the Department of Medical Oncology, British Columbia Cancer Agency, Vancouver, BC, Canada; the Department of Pathology and Radiation Oncology, British Columbia Cancer Agency, Vancouver, BC, Canada; and the University of British Columbia, Vancouver, BC, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donna L.","family":"Forrest","sequence":"additional","affiliation":[{"name":"From the Leukemia\/Bone Marrow Transplantation Program of British Columbia, Division of Hematology, Vancouver General Hospital, Vancouver, BC, Canada; the Department of Medical Oncology, British Columbia Cancer Agency, Vancouver, BC, Canada; the Department of Pathology and Radiation Oncology, British Columbia Cancer Agency, Vancouver, BC, Canada; and the University of British Columbia, Vancouver, BC, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Randy D.","family":"Gascoyne","sequence":"additional","affiliation":[{"name":"From the Leukemia\/Bone Marrow Transplantation Program of British Columbia, Division of Hematology, Vancouver General Hospital, Vancouver, BC, Canada; the Department of Medical Oncology, British Columbia Cancer Agency, Vancouver, BC, Canada; the Department of Pathology and Radiation Oncology, British Columbia Cancer Agency, Vancouver, BC, Canada; and the University of British Columbia, Vancouver, BC, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donna E.","family":"Hogge","sequence":"additional","affiliation":[{"name":"From the Leukemia\/Bone Marrow Transplantation Program of British Columbia, Division of Hematology, Vancouver General Hospital, Vancouver, BC, Canada; the Department of Medical Oncology, British Columbia Cancer Agency, Vancouver, BC, Canada; the Department of Pathology and Radiation Oncology, British Columbia Cancer Agency, Vancouver, BC, Canada; and the University of British Columbia, Vancouver, BC, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen H.","family":"Nantel","sequence":"additional","affiliation":[{"name":"From the Leukemia\/Bone Marrow Transplantation Program of British Columbia, Division of Hematology, Vancouver General Hospital, Vancouver, BC, Canada; the Department of Medical Oncology, British Columbia Cancer Agency, Vancouver, BC, Canada; the Department of Pathology and Radiation Oncology, British Columbia Cancer Agency, Vancouver, BC, Canada; and the University of British Columbia, Vancouver, BC, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John D.","family":"Shepherd","sequence":"additional","affiliation":[{"name":"From the Leukemia\/Bone Marrow Transplantation Program of British Columbia, Division of Hematology, Vancouver General Hospital, Vancouver, BC, Canada; the Department of Medical Oncology, British Columbia Cancer Agency, Vancouver, BC, Canada; the Department of Pathology and Radiation Oncology, British Columbia Cancer Agency, Vancouver, BC, Canada; and the University of British Columbia, Vancouver, BC, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clayton A.","family":"Smith","sequence":"additional","affiliation":[{"name":"From the Leukemia\/Bone Marrow Transplantation Program of British Columbia, Division of Hematology, Vancouver General Hospital, Vancouver, BC, Canada; the Department of Medical Oncology, British Columbia Cancer Agency, Vancouver, BC, Canada; the Department of Pathology and Radiation Oncology, British Columbia Cancer Agency, Vancouver, BC, Canada; and the University of British Columbia, Vancouver, BC, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin W.","family":"Song","sequence":"additional","affiliation":[{"name":"From the Leukemia\/Bone Marrow Transplantation Program of British Columbia, Division of Hematology, Vancouver General Hospital, Vancouver, BC, Canada; the Department of Medical Oncology, British Columbia Cancer Agency, Vancouver, BC, Canada; the Department of Pathology and Radiation Oncology, British Columbia Cancer Agency, Vancouver, BC, Canada; and the University of British Columbia, Vancouver, BC, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather J.","family":"Sutherland","sequence":"additional","affiliation":[{"name":"From the Leukemia\/Bone Marrow Transplantation Program of British Columbia, Division of Hematology, Vancouver General Hospital, Vancouver, BC, Canada; the Department of Medical Oncology, British Columbia Cancer Agency, Vancouver, BC, Canada; the Department of Pathology and Radiation Oncology, British Columbia Cancer Agency, Vancouver, BC, Canada; and the University of British Columbia, Vancouver, BC, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia L.","family":"Toze","sequence":"additional","affiliation":[{"name":"From the Leukemia\/Bone Marrow Transplantation Program of British Columbia, Division of Hematology, Vancouver General Hospital, Vancouver, BC, Canada; the Department of Medical Oncology, British Columbia Cancer Agency, Vancouver, BC, Canada; the Department of Pathology and Radiation Oncology, British Columbia Cancer Agency, Vancouver, BC, Canada; and the University of British Columbia, Vancouver, BC, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas J. S.","family":"Voss","sequence":"additional","affiliation":[{"name":"From the Leukemia\/Bone Marrow Transplantation Program of British Columbia, Division of Hematology, Vancouver General Hospital, Vancouver, BC, Canada; the Department of Medical Oncology, British Columbia Cancer Agency, Vancouver, BC, Canada; the Department of Pathology and Radiation Oncology, British Columbia Cancer Agency, Vancouver, BC, Canada; and the University of British Columbia, Vancouver, BC, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas J.","family":"Nevill","sequence":"additional","affiliation":[{"name":"From the Leukemia\/Bone Marrow Transplantation Program of British Columbia, Division of Hematology, Vancouver General Hospital, Vancouver, BC, Canada; the Department of Medical Oncology, British Columbia Cancer Agency, Vancouver, BC, Canada; the Department of Pathology and Radiation Oncology, British Columbia Cancer Agency, Vancouver, BC, Canada; and the University of British Columbia, Vancouver, BC, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2020021219513903000_REF1","unstructured":"Ferme\u0301 C, Mounier N, Divine\u0301 M, et al. Intensive salvage therapy with high-dose chemotherapy for patients with advanced Hodgkin's disease in relapse or failure after initial chemotherapy: results of the Groupe d'etudes des lymphomes de l'adulte H89 trial. J Clin Oncol.2002;20: 467-475."},{"key":"2020021219513903000_REF2","doi-asserted-by":"crossref","unstructured":"Moscowitz CH, Nimer SD, Zelenetz AD, et al. A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease: analysis by intent to treat and development of a prognostic model. Blood.2001;97: 616-623.","DOI":"10.1182\/blood.V97.3.616"},{"key":"2020021219513903000_REF3","doi-asserted-by":"crossref","unstructured":"Lazarus HM, Loberiza FR, Zhang M-J, et al. Autotransplants for Hodgkin's disease in first relapse or second remission: a report from the autologous blood and marrow transplant registry (ABMTR). Bone Marrow Transplant.2001;27: 387-396.","DOI":"10.1038\/sj.bmt.1702796"},{"key":"2020021219513903000_REF4","doi-asserted-by":"crossref","unstructured":"Sweetenham JW, Carella AM, Taghipour G, et al. High-dose therapy and autologous stem-cell transplantation for adult patients with Hodgkin's disease who do not enter remission after induction chemotherapy: results in 175 patients reported to the European Group for Blood and Marrow Transplantation. J Clin Oncol.1999;17: 3101-3109.","DOI":"10.1200\/JCO.1999.17.10.3101"},{"key":"2020021219513903000_REF5","doi-asserted-by":"crossref","unstructured":"Lazarus HM, Rowlings PA, Zhang M-J, et al. Autotransplants for Hodgkin's disease in patients never achieving remission: a report from the Autologous Blood and Marrow Transplant Registry. J Clin Oncol.1999;17: 534-545.","DOI":"10.1200\/JCO.1999.17.2.534"},{"key":"2020021219513903000_","doi-asserted-by":"crossref","unstructured":"Andre\u0301 M, Henry-Amar M, Pico J-L, et al. Comparison of high-dose therapy and autologous stem-cell transplantation with conventional therapy for Hodgkin's disease induction failure: a case-control study. J Clin Oncol.1999;17: 222-229.","DOI":"10.1200\/JCO.1999.17.1.222"},{"key":"2020021219513903000_","doi-asserted-by":"crossref","unstructured":"Sweetenham JW, Taghipour G, Milligan D, et al. High-dose therapy and autologous stem cell rescue for patients with Hodgkin's disease in first relapse after chemotherapy: results from the EBMT. Bone Marrow Transplant.1997;20: 745-752.","DOI":"10.1038\/sj.bmt.1700963"},{"key":"2020021219513903000_REF8","doi-asserted-by":"crossref","unstructured":"Reece DE, Barnett MJ, Shepherd JD, et al. High-dose cyclophosphamide, carmustine (BCNU), and etoposide (VP16-213) with or without cisplatin (CBV \u00b1 P) and autologous transplantation for patients with Hodgkin's disease who fail to enter a complete remission after combination chemotherapy. Blood.1995;86: 451-456.","DOI":"10.1182\/blood.V86.2.451.bloodjournal862451"},{"key":"2020021219513903000_REF9","doi-asserted-by":"crossref","unstructured":"Reece DE, Connors JM, Spinelli JJ, et al. Intensive therapy with cyclophosphamide, carmustine, etoposide \u00b1 cisplatin, and autologous bone marrow transplantation for Hodgkin's disease in first relapse after combination chemotherapy. Blood.1994;83: 1193-1199.","DOI":"10.1182\/blood.V83.5.1193.1193"},{"key":"2020021219513903000_","doi-asserted-by":"crossref","unstructured":"Linch DC, Winfield D, Goldstone AH, et al. Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial. Lancet.1993;341: 1051-1054.","DOI":"10.1016\/0140-6736(93)92411-L"},{"key":"2020021219513903000_REF11","doi-asserted-by":"crossref","unstructured":"Schmitz N, Pfistner B, Sextro M, et al. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haematopoietic stem-cell transplantation for relapsed chemo-sensitive Hodgkin's disease: a randomised trial. Lancet.2002;359: 2065-2071.","DOI":"10.1016\/S0140-6736(02)08938-9"},{"key":"2020021219513903000_REF12","doi-asserted-by":"crossref","unstructured":"Aleman BMP, van den Belt-Dusebout AW, Klokman WJ, Van't Veer MB, Bartelink H, Van Leeuwen FE. Long-term cause-specific mortality of patients treated for Hodgkin's disease. J Clin Oncol.2003;21: 3431-3439.","DOI":"10.1200\/JCO.2003.07.131"},{"key":"2020021219513903000_","doi-asserted-by":"crossref","unstructured":"Ng AK, Bernardo MP, Weller E, et al. Long-term survival and competing causes of death in patients with early-stage Hodgkin's disease treated at age 50 or younger. J Clin Oncol.2002;20: 2101-2108.","DOI":"10.1200\/JCO.2002.08.021"},{"key":"2020021219513903000_","doi-asserted-by":"crossref","unstructured":"Van Leeuwen FE, Klokman WJ, Van't Veer MB, et al. Long-term risk of second malignancy in survivors of Hodgkin's disease treated during adolescence or young adulthood. J Clin Oncol.2000;18: 487-497.","DOI":"10.1200\/JCO.2000.18.3.487"},{"key":"2020021219513903000_","doi-asserted-by":"crossref","unstructured":"Swerdlow AJ, Barber JA, Hudson GV, et al. Risk of second malignancy after Hodgkin's disease in a collaborative British cohort: the relation to age at treatment. J Clin Oncol.2000;18: 498-509.","DOI":"10.1200\/JCO.2000.18.3.498"},{"key":"2020021219513903000_REF16","doi-asserted-by":"crossref","unstructured":"Van Leeuwen FE, Klokman WJ, Hagenbeek A, et al. Second cancer risk following Hodgkin's disease: a 20-year follow-up study. J Clin Oncol.1994;12: 312-325.","DOI":"10.1200\/JCO.1994.12.2.312"},{"key":"2020021219513903000_REF17","doi-asserted-by":"crossref","unstructured":"Reece DE, Barnett MJ, Connors JM, et al. Intensive chemotherapy with cyclophosphamide, carmustine, and etoposide followed by autologous bone marrow transplantation for relapsed Hodgkin's disease. J Clin Oncol.1991;9: 1871-1879.","DOI":"10.1200\/JCO.1991.9.10.1871"},{"key":"2020021219513903000_REF18","doi-asserted-by":"crossref","unstructured":"Roach III M, Kapp DS, Rosenberg SA, Hoppe RT. Radiotherapy with curative intent: an option in selected patients relapsing after chemotherapy for advanced Hodgkin's disease. J Clin Oncol.1987;5: 550-555.","DOI":"10.1200\/JCO.1987.5.4.550"},{"key":"2020021219513903000_REF19","doi-asserted-by":"crossref","unstructured":"Sutcliffe SB, Wrigley PFM, Peto J, et al. MVPP chemotherapy regimen for advanced Hodgkin's disease. Br Med J.1978;1: 679-683.","DOI":"10.1136\/bmj.1.6114.679"},{"key":"2020021219513903000_REF20","doi-asserted-by":"crossref","unstructured":"Reece DE, Nevill TJ, Sayegh A, et al. Regimen-related toxicity and non-relapse mortality with high-dose cyclophosphamide, carmustine (BCNU) and etoposide (VP16-213) (CBV) and CBV plus cisplatin (CBVP) followed by autologous stem cell transplantation in patients with Hodgkin's disease. Bone Marrow Transplant.1999;23: 1131-1138.","DOI":"10.1038\/sj.bmt.1701790"},{"key":"2020021219513903000_REF21","doi-asserted-by":"crossref","unstructured":"Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc.1958;53: 457-481.","DOI":"10.1080\/01621459.1958.10501452"},{"key":"2020021219513903000_REF22","doi-asserted-by":"crossref","unstructured":"Gray JR. A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat.1988;16: 1141-1154.","DOI":"10.1214\/aos\/1176350951"},{"key":"2020021219513903000_REF23","doi-asserted-by":"crossref","unstructured":"Cox DR. Regression models and life tables. J R Stat Soc (B).1972;34: 187-220.","DOI":"10.1111\/j.2517-6161.1972.tb00899.x"},{"key":"2020021219513903000_REF24","doi-asserted-by":"crossref","unstructured":"Chopra R, McMillan AK, Linch DC, et al. The place of high-dose BEAM therapy and autologous bone marrow transplantation in poor-risk Hodgkin's disease. A single-center eight-year study of 155 patients. Blood.1993;81: 1137-1145.","DOI":"10.1182\/blood.V81.5.1137.1137"},{"key":"2020021219513903000_REF25","doi-asserted-by":"crossref","unstructured":"Schmitz N, Linch DC, Dreger P, et al. Randomised trial of filgrastim-mobilised peripheral blood progenitor cell transplantation versus autologous bone-marrow transplantation in lymphoma patients. Lancet.1996;347: 353.","DOI":"10.1016\/S0140-6736(96)90536-X"},{"key":"2020021219513903000_REF26","doi-asserted-by":"crossref","unstructured":"Fox KA, Lippmann SM, Cassady JR, Heusinkveld PS, Miller TP. Radiation therapy salvage of Hodgkin's disease following chemotherapy failure. J Clin Oncol.1987;5: 38-45.","DOI":"10.1200\/JCO.1987.5.1.38"},{"key":"2020021219513903000_REF27","doi-asserted-by":"crossref","unstructured":"Bolwell B, Kalaycio M, Goormastic M, et al. Progressive disease after ABMT for Hodgkin's disease. Bone Marrow Transplant.1997;20: 761-765.","DOI":"10.1038\/sj.bmt.1700974"},{"key":"2020021219513903000_REF28","doi-asserted-by":"crossref","unstructured":"Metayer C, Curtis RE, Vose J, et al. Myelodysplastic syndrome and acute myeloid leukemia after autotransplantation for lymphoma: a multi-center case-control study. Blood.2003;101: 2015-2023.","DOI":"10.1182\/blood-2002-04-1261"},{"key":"2020021219513903000_","doi-asserted-by":"crossref","unstructured":"Akpek G, Ambinder RF, Piantadosi S, et al. Long-term results of blood and marrow transplantation for Hodgkin's lymphoma. J Clin Oncol.2001;19: 4314-4321.","DOI":"10.1200\/JCO.2001.19.23.4314"},{"key":"2020021219513903000_","doi-asserted-by":"crossref","unstructured":"Milligan DW, Ruiz de Elvira MC, Kolb H-J, et al. Secondary leukaemia and myelodysplasia after autografting for lymphoma: results from the EBMT. Br J Haematol.1999;106: 1020-1026.","DOI":"10.1046\/j.1365-2141.1999.01627.x"},{"key":"2020021219513903000_REF31","doi-asserted-by":"crossref","unstructured":"Sureda A, Iriondo A, Carreras E, et al. Autologous stem-cell transplantation for Hodgkin's disease: results and prognostic factors in 494 patients from the Grupo Espan\u0303ol de Linfomas\/Transplante Auto\u0301logo de Me\u0301dula O\u0301sea Spanish Cooperative Group. J Clin Oncol.2001;19: 1395-1404.","DOI":"10.1200\/JCO.2001.19.5.1395"},{"key":"2020021219513903000_REF32","unstructured":"Andre\u0301 M, Henry-Amar M, Blaise D, et al. Treatment-related deaths and second cancer risk after autologous stem cell transplantation for Hodgkin's disease. Blood.1998;92: 1933-1940."},{"key":"2020021219513903000_REF33","unstructured":"Forrest DL, Hogge DE, Lavoie JC, et al. High-dose chemotherapy (HDCT) and autologous hematopoietic stem cell transplantation (AHSCT) does not increase the risk of second neoplasms for patients with Hodgkin's lymphoma: a comparison of conventional therapy alone versus conventional therapy followed by AHSCT [abstract]. Blood.2003;102: 116a."},{"key":"2020021219513903000_REF34","doi-asserted-by":"crossref","unstructured":"Hancock SL, Tucker MA, Hoppe RT. Factors affecting late mortality from heart disease after treatment of Hodgkin's disease. JAMA.1993;270: 1949-1955.","DOI":"10.1001\/jama.1993.03510160067031"},{"key":"2020021219513903000_REF35","doi-asserted-by":"crossref","unstructured":"Boivin J-F, Hutchison GB, Lubin JH, Mauch P. Coronary artery disease mortality in patients treated for Hodgkin's disease. Cancer.1992;69: 1241-1247.","DOI":"10.1002\/cncr.2820690528"},{"key":"2020021219513903000_REF36","doi-asserted-by":"crossref","unstructured":"Henry-Amar M, Joly F. Late complications after Hodgkin's disease. Ann Oncol.1996;4: 115-126.","DOI":"10.1093\/annonc\/7.suppl_4.S115"},{"key":"2020021219513903000_REF37","doi-asserted-by":"crossref","unstructured":"Guillaume T, Rubinstein DB, Symann M. Immune reconstitution and immunotherapy after autologous hematopoietic stem cell transplantation. Blood.1998;92: 1471-1490.","DOI":"10.1182\/blood.V92.5.1471"},{"key":"2020021219513903000_REF38","doi-asserted-by":"crossref","unstructured":"Hensel M, Egerer G, Schneeweiss A, Goldschmidt H, Ho AD. Quality of life and rehabilitation in social and professional life after autologous stem cell transplantation. Ann Oncol.2002;13: 209-217.","DOI":"10.1093\/annonc\/mdf031"},{"key":"2020021219513903000_REF39","doi-asserted-by":"crossref","unstructured":"Schimmer AD, Elliott ME, Abbey SE, et al. Illness intrusiveness among survivors of autologous blood and marrow transplantation. Cancer.2001;92: 147-154.","DOI":"10.1002\/1097-0142(20011215)92:12<3147::AID-CNCR10168>3.0.CO;2-C"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/106\/4\/1473\/1712335\/zh801605001473.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/106\/4\/1473\/1712335\/zh801605001473.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,25]],"date-time":"2024-01-25T15:51:23Z","timestamp":1706197883000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/106\/4\/1473\/21548\/Highdose-chemotherapy-and-autologous-stem-cell"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,8,15]]},"references-count":39,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2005,8,15]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2004-12-4689","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,8,15]]}}}